Breast Diseases Clinical Trials

9 recruitingLast updated: June 17, 2026

There are 9 actively recruiting breast diseases clinical trials across 14 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 4. Top locations include Milan, Italy, Naples, Italy, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Breast Diseases Trials at a Glance

9 actively recruiting trials for breast diseases are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Milan, Naples, and Los Angeles. Lead sponsors running breast diseases studies include Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Fujian Cancer Hospital, and FangYi.

Browse breast diseases trials by phase

Treatments under study

About Breast Diseases Clinical Trials

Looking for clinical trials for Breast Diseases? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Breast Diseases trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Breast Diseases clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 2

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Breast NeoplasmsBreast DiseasesCDK4/6 Inhibitor+3 more
Fujian Cancer Hospital2,000 enrolled2 locationsNCT07581834
Recruiting

Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models

Breast NeoplasmsBreast DiseasesUltrasonography
Peking Union Medical College Hospital1,380 enrolled1 locationNCT07500428
Recruiting

A Study of Breast Cancer Risk Factors and Outcomes of People in Florida

Breast CancerBreast NeoplasmsBreast Diseases
Memorial Sloan Kettering Cancer Center800 enrolled3 locationsNCT06780176
Recruiting
Phase 2

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.

Breast CancerBreast NeoplasmsBreast Diseases
Maastricht University Medical Center20 enrolled1 locationNCT06335069
Recruiting

A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients

Breast NeoplasmsBreast DiseasesQuality of Life (QOL)+1 more
FangYi3,000 enrolled3 locationsNCT07010939
Recruiting
Not Applicable

Breast 3DUS ABUS System Comparison

Breast Diseases
Western University, Canada30 enrolled1 locationNCT06118996
Recruiting
Phase 4

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Breast CancerHeart FailureBreast Diseases+10 more
Silesian Centre for Heart Diseases600 enrolled4 locationsNCT05465031
Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Breast CancerBreast Cancer MetastaticBreast Carcinoma+37 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano3,500 enrolled24 locationsNCT06805812